Tests MZE829 in adults with APOL1-related protein-leaking kidney disease
Tests the drug MZE829 in adults with kidney disease linked to the APOL1 gene.
Plain-language title generated from the registry record
Registry title: A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
Key facts
- Where
- Leicester and London, United KingdomSee the 2 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-term kidney disease and protein in the urine who carry a high-risk APOL1 gene type.
- Age
- 18 Years to 68 Years
- Sex
- All sexes can join.
- Disease stage
- Chronic kidney disease with persistent albuminuria (protein in the urine).
- Biomarker or test result
- APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2.
Main reasons for not taking part
- Organ or bone marrow transplantation
- Active cancer within the past 2 years (some treated early cancers are allowed)
- Conditions that may change how the drug is absorbed, such as bariatric surgery
- Type I diabetes
- Pregnant or currently nursing
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 68 years old?
Source: NCT06830629, who can take part
Where in United Kingdom
- LeicesterLeicester, United KingdomTaking people
- LondonLondon, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Maze Therapeutics
- Trial code
- NCT06830629
- Record updated
- 27 July 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.Read full original descriptionShow less
An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.
Inclusion: APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2; Chronic kidney disease with persistent albuminuria.
Exclusion: Organ or bone marrow transplantation; History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer; Conditions that may alter drug absorption, e.g., history of bariatric surgery; Type I diabetes; Pregnant or currently nursing; Other inclusion/exclusion criteria defined in protocol apply.